Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression

The goal of this Phase 1 clinical trial is to understand whether a new experimental treatment, called ORM-1153, will be a safe and possibly effective treatment option for participants with blood cancers such as Acute Myeloid Leukemia (AML) which have a particular protein (called Cluster of Differentiation 123 or CD123) on the cancer cell's surface. Phase 1 studies are designed to find a safe and effective dose. Participants will be receiving ORM-1153 at the defined study frequency as an infusion into the vein. They will need to visit the clinic frequently during the first few months of treatm

Trial Details

NCT ID

NCT07809906

Phase

PHASE1

Sponsor

Orum Therapeutics USA, Inc.

Status

RECRUITING

Cancer Type

Leukemia

Interventions

ORM-1153

Locations (sample)

Grand Rapids, Michigan, United States|42.96336,-85.66809
Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Adults ≥18 years of age (or ≥19 years of age according to local regulatory guidelines) at the time of signature of the informed consent form.
Documented diagnosis of relapsed or refractory AML with any detectable level of CD123 as evaluated by local assessment.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Adequate organ and coagulation function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →